View Older Stories View More Recent Stories

Mar 12, 2020 05:59AM Merck (MRK), AstraZeneca (AZN) Report Update on Phase 3 GY004 for Cediranib & LYNPARZA (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Mar 12, 2020 03:00AM Update on Phase 3 GY004 for Cediranib and LYNPARZA® (olaparib) in Platinum-Sensitive Relapsed Ovarian Cancer
Mar 4, 2020 06:45AM Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite
Mar 3, 2020 02:00PM MilliporeSigma's New LANEXO™ System to Improve Scientists' Productivity in the Lab
Mar 2, 2020 06:45AM Merck Announces New Data from Broad HIV Program at CROI 2020
Mar 2, 2020 06:31AM Merck's (MRK) KEYTRUDA Significantly Improved PSF Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory cHL
Mar 2, 2020 06:30AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Feb 27, 2020 06:45AM Merck to Present at the Cowen Health Care Conference
Feb 18, 2020 07:17PM Merck Receives Complete Response Letter from the US FDA for Supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab) Six-Week Dosing Schedule
Feb 14, 2020 11:20AM ERVEBO® (Ebola Zaire Vaccine, Live) Now Registered in Four African Countries, Within 90 Days of Reference Country Approval and WHO Prequalification
Feb 12, 2020 06:52AM Merck's (MRK) KEYTRUDA in Combination with Chemotherapy Met Primary Endpoint of PFS as First-Line Treatment for mTNBC
Feb 12, 2020 06:45AM Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (mTNB
Feb 5, 2020 06:47AM Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results
Feb 5, 2020 06:46AM Merck (MRK) Announces Spinoff of Women�s Health, Trusted Legacy Brands and Biosimilars Products
Feb 5, 2020 06:45AM Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company (“NewCo”)
Feb 3, 2020 06:46AM Merck (MRK) Reports FDA Acceptance for sNDA Review for RECARBRIO (imipenem, cilastatin, and relebactam)
Feb 3, 2020 06:45AM FDA Accepts For Review Supplemental New Drug Application (sNDA) for RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bac
Jan 31, 2020 04:08PM Merck (MRK) Reports Election of Dr. Christine Seidman and Kathy Warden to Board
Jan 31, 2020 04:05PM Dr. Christine Seidman and Kathy Warden Elected to Merck Board of Directors
Jan 28, 2020 01:21PM Merck Announces Second-Quarter 2020 Dividend
Jan 28, 2020 02:00AM Lung Cancer Study Shows Barriers in Patient Access to Care in Europe
Jan 27, 2020 06:47AM Merck (MRK) Reports FDA Approval of DIFICID (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older
Jan 27, 2020 06:45AM FDA Approves Merck’s DIFICID® (fidaxomicin) to Treat Clostridioides difficile in Children Aged Six Months and Older
Jan 21, 2020 06:55AM FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in HRR-Mutated Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
Jan 18, 2020 09:00AM Significant Study on Veterinary Wellbeing Reveals Importance of Continued Focus on Personal and Professional Health and Wellbeing Among Veterinarians
Jan 16, 2020 08:34AM Merck (MRK) Completes Acquisition of ArQule (ARQL)
Jan 16, 2020 08:34AM Merck Completes Acquisition of ArQule
Jan 8, 2020 04:33PM Merck (MRK) Announces FDA Approved its KEYTRUDA for Patients With BCG-Unresponsive, High-Risk, NMIBC With CIS With or Without Papillary Tumors
Jan 8, 2020 04:31PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Inel
Jan 6, 2020 04:06PM Merck's (MRK) KEYTRUDA in Combination with Chemotherapy Significantly Improved PFS Compared to Chemotherapy Alone as First-Line Treatment for ES-SCLC
Jan 6, 2020 04:05PM Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small
Jan 6, 2020 07:00AM BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Jan 6, 2020 06:31AM Merck (MRK) Announces Strategic Oncology Collaboration with Taiho and Astex
Jan 6, 2020 06:30AM Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
Jan 3, 2020 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2019 Sales and Earnings Conference Call on February 5
Jan 2, 2020 06:45AM Merck to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 30, 2019 06:55AM LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
Dec 20, 2019 07:16AM Merck (MRK) Confirms FDA Approval for ERVEBO (Ebola Zaire Vaccine, Live)
Dec 20, 2019 07:15AM Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live)
Dec 20, 2019 06:46AM Merck's (MRK) KEYTRUDA Approved in Japan for Three New First-Line Indications Across Advanced RCC and Recurrent or Distant Metastatic Head and Neck Cancer
Dec 20, 2019 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer
Dec 19, 2019 08:00AM MilliporeSigma Licenses Foundational CRISPR Integration Technology to Promega
Dec 17, 2019 05:16PM Merck (MRK) Announces FDA ODAC Recommends KEYTRUDA for Treatment of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer
Dec 17, 2019 05:15PM FDA Oncologic Drugs Advisory Committee (ODAC) Recommends KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)
Dec 17, 2019 05:00PM Merck Animal Health Completes Acquisition of Vaki to Further Broaden Its Leadership Position in Aquaculture to Advance Fish Health and Welfare
Dec 17, 2019 02:10PM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA Recommended by FDA Advisory Committee for First-Line Maintenance Therapy in Germline BRCA-Mutated Metastatic Pancreatic Cancer
Dec 17, 2019 02:09PM LYNPARZA® (olaparib) Recommended by FDA Advisory Committee for First-Line Maintenance Therapy in Germline BRCA-Mutated Metastatic Pancreatic Cancer That Has Not Progressed on Platinum-Based Chemother
Dec 17, 2019 06:46AM Merck (MRK) Begins Tender Offer to Acquire ArQule (ARQL)
Dec 17, 2019 06:45AM Merck Begins Tender Offer to Acquire ArQule
Dec 12, 2019 06:47AM Merck (MRK) Reports Data from Exploratory Analysis Shows KEYTRUDA (pembrolizumab) Improved OS as Monotherapy for First-Line Treatment of Metastatic NSCLC
View More Recent Stories View Older Stories